Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
A number of specific PPLs, a group of prenylflavanone compounds, some novel, were isolated, identified and tested at as low as 0.04 μg/mL to be able to increase survival of neural stem cells, to promote neuronal growth with lengthening of neurite More
A novel non-invasive method for using carbon-13 magnetization transfer effects to determine and evaluate in vivo aspartate transaminase (AST) activity and levels in an organ, as a biomarker of disease and certain neurological disorders. More
A non-transgenic, adult onset rodent model for Alzheimer's disease and stroke. More
Treatment of cognitive and learning impairment through the use of a bacterial toxins called CNF1 . More
KD501 is a partially purified extract from Scrophulariae Radix, which shows an efficacy for the treatment of strokes and degenerated neuronal disease in vivo. Elcom filed an IND application with the KFDA (The Korea Food & Drug Administration) in May More
These radioactive compounds have the very unique and unprecedented ability to bind very specifically and irreversibly to butyrylcholinesterase (BChE). More
For use as amyloid plaque binding ligands in non-invasive early detection of AD and other neuronal protein aggregation disorders. More
Reperfusions can lead to sever damage in patients with heat attacks and strokes, the SOD-nanoparticles would be highly beneficial for use in hospitals for treating these patients. More
Overexpressed in Werner's Syndrome Fibroblasts More
Overexpressed in Werner's Syndrome Fibroblasts More
Your selection
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us